Join to View Full Profile
2201 Inwood Rd Seay Biomedical Building 2nd floorDallas, TX 75390
Phone+1 214-645-4673
Dr. Gerber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2000 - 2004
Weill Cornell MedicineClass of 2000
Certifications & Licensure
TX State Medical License 2002 - 2026
MD State Medical License 2004 - 2008
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2005 Jun 01
- Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2009 Sep 01
- Clinical Trial of ARQ 761 in Advanced Solid Tumors Start of enrollment: 2011 Dec 29
- Join now to see all
Publications & Presentations
PubMed
- Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors.Matthew E Campbell, Sonja Stutzman, Sharon Primeaux, Deseray Sida, Minjae Lee
Pediatric Blood & Cancer. 2025-12-01 - Radiologists' Perceptions of the 21st Century Cures Act.Jessica H Porembka, Emily L Paton, Yin Xi, Ruth C Carlos, Sheena Bhalla
Journal of the American College of Radiology. 2025-10-02 - Innate and adaptive immune features associated with immune-related adverse events.Shaheen Khan, Venkat S Malladi, Mitchell S von Itzstein, Hong Mu-Mosley, Farjana J Fattah
Journal for Immunotherapy of Cancer. 2025-09-10
Journal Articles
- Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published CasesDavid E Gerber, Jonathan E Dowell, Clinical Lung Cancer
Lectures
- Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical TrialsClinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Underlying host immune dysregulation in cancer patients developing immune-related adverse events.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Authored Content
- Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published CasesNovember 2018
Press Mentions
Crizotinib Not Beneficial in Resected Early ALK+NSCLCSeptember 10th, 2025- Crizotinib Fails to Improve Disease-Free Survival in Resected Early-Stage ALK+ Non-Small Cell Lung CancerSeptember 7th, 2025
- New Law Allows Physicians to Help Patients Receive Their Medical News – Good or BadAugust 19th, 2025
- Join now to see all
Grant Support
- UT Southwestern Simmons Comprehensive Cancer Center Clinical Oncology Research Career Development AwardUT SOUTHWESTERN MEDICAL CENTER2025–2030
- UT Southwestern Simmons Comprehensive Cancer Center Clinical Oncology Research Career Development AwardUT SOUTHWESTERN MEDICAL CENTER2025–2030
- TCR-antigen foundation model to empower TCR-based diagnostics and therapeuticsUNIVERSITY OF TX MD ANDERSON CAN CTR2025–2030
- Finding the optimal balance of immunotherapy efficacy and toxicity.UT SOUTHWESTERN MEDICAL CENTER2020–2025
- UT Southwestern NCI National Clinical Trials Network Lead Academic SiteUT SOUTHWESTERN MEDICAL CENTER2019–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
